Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adoptEITF, aflibercept, allopurinol, andEITF, androgen, arcalysttm, ARCALYSTTMin, arrange, arrangement, ARVO, beotherthan, blinded, bound, Brazil, breach, calledVelocImmune, Canada, choose, concentration, corroboration, cut, delinquent, died, disagree, dispute, dissolution, docetaxel, drafted, driven, economic, elbow, ensuing, entirety, exempt, fight, filer, front, gemcitabine, Germany, glucocorticoid, greatest, hedge, imdertaken, IND, indirectly, infection, inflow, inRule, instability, IntegratedFramework, intestinal, intraarticular, intracellulare, inWet, Israel, itsVelociGenetechnology, itsVelocImmune, Japanese, KGaA, Kingdom, knowledge, land, landscape, launch, longest, mark, Mexico, minimal, mitigate, mycobacteria, mycobacterium, NE, nonfinancial, NY, ofEfficacy, ofEITF, ofRegulation, ordinary, ourvelocigene, OurVelociGeneplatform, ourVelociGenetechnology, ourVelocImmune, ourVelocImmunehuman, ourVelocImmunemice, ourVelocImmunetechnology, oversee, paper, perforation, persistent, pneumoniae, polymayalgia, preceding, priority, prohibit, prohibition, proportionally, proportionately, proprietaryVelociGene, ranibizumab, recommended, refinance, refinancing, reformatted, remediate, remediation, repay, resolve, robust, screening, seasoned, shell, slated, sliding, slight, solicitation, span, standstill, StatementNo, suspected, technologyVelocImmune®and, theVelocImmune, TheVelocImmunemice, TheVelocImmunemouse, theVelocImmunetechnology, TheVelociMousetechnology, thirty, thisForm, timeline, toVelocImmuneand, UK, unblinded, uncommon, undertaken, underwriter, underwritten, unpaid, upfront, uric, VIEW, wider, winding, worse, Xoma
Removed:
achievement, approximate, bore, calendar, ciliary, CNTF, compounded, enterprise, Eric, flexibility, forgave, guidance, hurt, integration, LIBOR, loan, neurotrophic, notified, NW, obesity, older, proceed, receiving, repayment, replenishment, represented, Retainer, Shooter, slightly, spectrum, threshold, updated, velocigene
Filing tables
Filing exhibits
- 10-K Annual report
- 3.1 EX-3.1: Restated Certificate of Incorporation
- 10.18 EX-10.18: Discovery and Preclinical Development Agreemnet
- 10.19 EX-10.19: License and Collaboration Agreement
- 10.20 EX:10.20: Stock Purchase Agreement
- 10.21 EX-10.21: Investor Agreement
- 12.1 EX-12.1: Statement Re: Computation of Ratio of Earnings to Combined Fixed Charges
- 23.1 EX-23.1: Consent of Pricewaterhousecoopers LLP
- 31.1 EX-31.1: Certification
- 31.2 EX-31.2: Certification
- 32 EX-32: Certification
REGN similar filings
Filing view
External links
Exhibit 32
Certification of CEO and CFO Pursuant to
18 U.S.C. Section 1350,
As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
18 U.S.C. Section 1350,
As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Annual Report of Regeneron Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Leonard S. Schleifer, M.D., Ph.D., as Chief Executive Officer of the Company, and Murray A. Goldberg, as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
/s/ LEONARD S. SCHLEIFER | ||
Leonard S. Schleifer, M.D., Ph.D. | ||
Chief Executive Officer | ||
February 27, 2008 | ||
/s/ MURRAY A. GOLDBERG | ||
Murray A. Goldberg | ||
Chief Financial Officer | ||
February 27, 2008 |